Talaris Therapeutics Probability of Future Stock Price Finishing Under 1.63
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
Talaris |
Talaris Therapeutics Target Price Odds to finish below 1.63
The tendency of Talaris Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 1.63 or more in 90 days |
| 2.98 | 90 days | 1.63 | near 1 |
Based on a normal probability distribution, the odds of Talaris Therapeutics to drop to $ 1.63 or more in 90 days from now is near 1 (This Talaris Therapeutics probability density function shows the probability of Talaris Stock to fall within a particular range of prices over 90 days) . Probability of Talaris Therapeutics price to stay between $ 1.63 and its current price of $2.98 at the end of the 90-day period is about 77.89 .
Given the investment horizon of 90 days Talaris Therapeutics has a beta of -0.31. This usually implies as returns on the benchmark increase, returns on holding Talaris Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Talaris Therapeutics is likely to outperform the market. Additionally Talaris Therapeutics has an alpha of 0.5664, implying that it can generate a 0.57 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Talaris Therapeutics Price Density |
| Price |
Predictive Modules for Talaris Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Talaris Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Talaris Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Talaris Therapeutics is not an exception. The market had few large corrections towards the Talaris Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Talaris Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Talaris Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.57 | |
β | Beta against Dow Jones | -0.31 | |
σ | Overall volatility | 0.26 | |
Ir | Information ratio | 0.11 |
Talaris Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Talaris Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Talaris Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Talaris Therapeutics is not yet fully synchronised with the market data | |
| Talaris Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (73.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Talaris Therapeutics currently holds about 207.11 M in cash with (60.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 78.0% of the company shares are owned by institutional investors |
Talaris Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Talaris Stock often depends not only on the future outlook of the current and potential Talaris Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Talaris Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.2 M | |
| Cash And Short Term Investments | 181.3 M |
Talaris Therapeutics Technical Analysis
Talaris Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Talaris Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Talaris Therapeutics. In general, you should focus on analyzing Talaris Stock price patterns and their correlations with different microeconomic environments and drivers.
Talaris Therapeutics Predictive Forecast Models
Talaris Therapeutics' time-series forecasting models is one of many Talaris Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Talaris Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Talaris Therapeutics
Checking the ongoing alerts about Talaris Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Talaris Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Talaris Therapeutics is not yet fully synchronised with the market data | |
| Talaris Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (73.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Talaris Therapeutics currently holds about 207.11 M in cash with (60.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 78.0% of the company shares are owned by institutional investors |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |